Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Molecular profiling of cancer at the transcript level has become routine. Large-scale analysis of proteomic alterations during cancer progression has been a more daunting task. Here, we employed high-throughput immunoblotting in order to interrogate tissue extracts derived from prostate cancer. We identified 64 proteins that were altered in prostate cancer relative to benign prostate and 156 additional proteins that were altered in metastatic disease. An integrative analysis of this compendium of proteomic alterations and transcriptomic data was performed, revealing only 48%-64% concordance between protein and transcript levels. Importantly, differential proteomic alterations between metastatic and clinically localized prostate cancer that mapped concordantly to gene transcripts served as predictors of clinical outcome in prostate cancer as well as other solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 4×
“In 95 primary breast adenocarcinomas (van ’t Veer et al., 2002), tumors bearing the 50-gene concordant progression signature were more likely to progress to metastasis than those lacking this signature (p = 0.0025; Supplemental Data).”
BackgroundMethodInfluentialMissing Value Estimation Methods for DNA Microarrays
Troyanskaya, O., Cantor, M., Sherlock, G., Brown, P., Hastie, T., Tibshirani, R., Botstein, D., & Altman, R. B. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.6.520 · Cited by 4,230
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationThe polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717 · cited 9×
“While examining concordant proteomic alterations, interestingly, we found that EZH2, a polycomb group protein that we and others have previously characterized as being overexpressed in aggressive prostate and breast cancer (Kleer et al., 2003; Varambally et al., 2002) was one of the 50 proteins identified as being con…”
BackgroundMethodResultInfluentialSelf-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Cited by
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Self-citationAndrogen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Self-citationGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA
Wang, D., Garcia-Bassets, I., Benner, C., Li, W., Su, X., Zhou, Y., Qiu, J., Liu, W., Kaikkonen, M. U., Ohgi, K. A., et al. (2011) · Nature · doi:10.1038/nature10006 · Cited by 827
Genetic determinants of cancer metastasis
Nguyen, D. X., & Massagué, J. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2101 · Cited by 801
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
Hollander, M. C., Blumenthal, G. M., & Dennis, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3037 · Cited by 794
Prensner, J. R., Iyer, M. K., Sahu, A., Asangani, I. A., Cao, Q., Patel, L., Vergara, I. A., Davicioni, E., Erho, N., Ghadessi, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2771 · Cited by 669
Self-citationErho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066855 · Cited by 644
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer
Chakravarty, D., Sboner, A., Nair, S. S., Giannopoulou, E., Li, R., Hennig, S., Mosquera, J. M., Pauwels, J., Park, K., Kossai, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6383 · Cited by 621
Self-citationImmunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy
Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E., Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., et al. (2015) · Nature · doi:10.1038/nature14395 · Cited by 611
IAP-targeted therapies for cancer
LaCasse, E. C., Mahoney, D. J., Cheung, H. H., Plenchette, S., Baird, S., & Korneluk, R. G. (2008) · Oncogene · doi:10.1038/onc.2008.302 · Cited by 524
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression
Furic, L., Rong, L., Larsson, O., Koumakpayi, I. H., Yoshida, K., Brueschke, A., Petroulakis, E., Robichaud, N., Pollak, M., Gaboury, L. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005320107 · Cited by 519
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
Gurel, B., Iwata, T., M Koh, C., Jenkins, R. B., Lan, F., Van Dang, C., Hicks, J. L., Morgan, J., Cornish, T. C., Sutcliffe, S., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.111 · Cited by 441
Sharma, N. L., Massie, C. E., Ramos-Montoya, A., Zecchini, V., Scott, H. E., Lamb, A. D., MacArthur, S., Stark, R., Warren, A. Y., Mills, I. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.010 · Cited by 405
The Pivotal Regulatory Landscape of RNA Modifications
Li, S., & Mason, C. E. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090413-025405 · Cited by 374
Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
Kuo, C.-L., Ponneri Babuharisankar, A., Lin, Y.-C., Lien, H.-W., Lo, Y. K., Chou, H.-Y., Tangeda, V., Cheng, L.-C., Cheng, A. N., & Lee, A. Y.-L. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00859-2 · Cited by 351
A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome
Yu, J., Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., Wang, X., Ghosh, D., Shah, R. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2498 · Cited by 348
Self-citationUp-Regulation of Dicer, a Component of the MicroRNA Machinery, in Prostate Adenocarcinoma
Chiosea, S., Jelezcova, E., Chandran, U., Acquafondata, M., McHale, T., Sobol, R. W., & Dhir, R. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060480 · Cited by 347
Self-citationSharma, A., Yeow, W.-S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44239 · Cited by 331
Qin, J., Liu, X., Laffin, B., Chen, X., Choy, G., Jeter, C. R., Calhoun-Davis, T., Li, H., Palapattu, G. S., Pang, S., et al. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.03.009 · Cited by 317
Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19
Hua, J. T., Ahmed, M., Guo, H., Zhang, Y., Chen, S., Soares, F., Lu, J., Zhou, S., Wang, M., Li, H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.014 · Cited by 315
Ross-Adams, H., Lamb, A. D., Dunning, M. J., Halim, S., Lindberg, J., Massie, C. M., Egevad, L. A., Russell, R., Ramos-Montoya, A., Vowler, S. L., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.07.017 · Cited by 310
Koh, C. M., Bieberich, C. J., Dang, C. V., Nelson, W. G., Yegnasubramanian, S., & De Marzo, A. M. (2010) · Genes & Cancer · doi:10.1177/1947601910379132 · Cited by 296
Shema, E., Tirosh, I., Aylon, Y., Huang, J., Ye, C., Moskovits, N., Raver-Shapira, N., Minsky, N., Pirngruber, J., Tarcic, G., et al. (2008) · Genes & Development · doi:10.1101/gad.1703008 · Cited by 287
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
Akamatsu, S., Wyatt, A. W., Lin, D., Lysakowski, S., Zhang, F., Kim, S., Tse, C., Wang, K., Mo, F., Haegert, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.012 · Cited by 279
Self-citationPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Androgen‐responsive long noncoding RNA CTBP1‐AS promotes prostate cancer
Takayama, K., Horie‐Inoue, K., Katayama, S., Suzuki, T., Tsutsumi, S., Ikeda, K., Urano, T., Fujimura, T., Takagi, K., Takahashi, S., et al. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.99 · Cited by 278
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 275
CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis
Wang, L., Zhao, Z., Meyer, M. B., Saha, S., Yu, M., Guo, A., Wisinski, K. B., Huang, W., Cai, W., Pike, J. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.007 · Cited by 264
Functional proteomic profiling of AML predicts response and survival
Kornblau, S. M., Tibes, R., Qiu, Y. H., Chen, W., Kantarjian, H. M., Andreeff, M., Coombes, K. R., & Mills, G. B. (2009) · Blood · doi:10.1182/blood-2007-10-119438 · Cited by 263
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor
Massie, C. E., Adryan, B., Barbosa‐Morais, N. L., Lynch, A. G., Tran, M. G., Neal, D. E., & Mills, I. G. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7401046 · Cited by 259
Izumi, K., Fang, L., Mizokami, A., Namiki, M., Li, L., Lin, W., & Chang, C. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202367 · Cited by 247
“…AR silencing to CCL2 in other experimental settings, we analysed microarray studies deposited in the public NCBI database (Varambally et al, 2005); (Wang et al, 2007), we took advantage of these gene ‐ pro fi ling databases and found increased CCL2 expression in PCa tissues (Supporting…”
Ding, Z., Wu, C.-J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Protopopov, A., Chu, G. C., Wang, G., Lu, X., Labrot, E. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.039 · Cited by 220
“Thus, we utilized the expression profile data in metastatic versus primary tumors from six prostate cancer cohorts on Oncomine (Lapointe et al., 2004; LaTulippe et al., 2002; Vanaja et al., 2003; Varambally et al., 2005; Yu et al., 2004; Holzbeierlein et al., 2004) to define the subset of genes exhibiting a progressio…”
InfluentialAndrogens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch
Tennakoon, J. B., Shi, Y., Han, J. J., Tsouko, E., White, M. A., Burns, A. R., Zhang, A., Xia, X., Ilkayeva, O. R., Xin, L., et al. (2014) · Oncogene · doi:10.1038/onc.2013.463 · Cited by 205
Stathmin: a protein with many tasks. New biomarker and potential target in cancer
Belletti, B., & Baldassarre, G. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.620951 · Cited by 199
“Moreover, the fact that the microtubule-stabilizing protein microtubule associated protein 2 (MAP2) is downregulated in metastatic melanomas respect to primary tumors [107] whereas stathmin is overexpressed in metastatic versus clinically localized prostate carcinomas [108], invasive recurrent hepatocarcinomas [109],…”
BackgroundThe role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis
Frohlich, D. A., McCabe, M. T., Arnold, R. S., & Day, M. L. (2008) · Oncogene · doi:10.1038/onc.2008.79 · Cited by 192
“…Luo et al., 2001; Magee et al., 2001; Welsh et al., 2001; LaTulippe et al., 2002; Glinsky et al., 2004; Lapointe et al., 2004; Yu et al., 2004; Varambally et al., 2005; Vanaja et al., 2006) in which prostate tumor samples were compared to benign prostate tissue, Nrf2 was significantly…”
BackgroundPuhr, M., Hoefer, J., Eigentler, A., Ploner, C., Handle, F., Schaefer, G., Kroon, J., Leo, A., Heidegger, I., Eder, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0989 · Cited by 171
“For prostate cancer, the VaramballyProstate (34), Wallace-Prostate (35), Arredouani-Prostate (36), and Vanaja-Prostate (37) datasets showed significantly reduced GR gene expression in cancerous tissues (Fig.”
BackgroundWang, Q., Bailey, C. G., Ng, C., Tiffen, J., Thoeng, A., Minhas, V., Lehman, M. L., Hendy, S. C., Buchanan, G., Nelson, C. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1821 · Cited by 165
“We analyzed LAT1 and LAT3 expression in silico using publically available microarray data from GDS1439 (34), GDS2545 (35, 36), and Holzbeierlein and colleagues (37).”
The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy
Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M., & Pienta, K. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.4.225 · Cited by 161
Self-citationEzponda, T., Popovic, R., Shah, M. Y., Martinez-Garcia, E., Zheng, Y., Min, D.-J., Will, C., Neri, A., Kelleher, N. L., Yu, J., et al. (2013) · Oncogene · doi:10.1038/onc.2012.297 · Cited by 158
Self-citationIntegrative epigenetic taxonomy of primary prostate cancer
Stelloo, S., Nevedomskaya, E., Kim, Y., Schuurman, K., Valle-Encinas, E., Lobo, J., Krijgsman, O., Peeper, D. S., Chang, S. L., Feng, F. Y.-C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07270-2 · Cited by 154
Proteomics in Clinical Trials and Practice
Azad, N. S., Rasool, N., Annunziata, C. M., Minasian, L., Whiteley, G., & Kohn, E. C. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r600008-mcp200 · Cited by 85
“Proteomic changes between localized and metastatic cancer that were concordant with differences in gene transcription did predict clinical outcome, indicating a potential integrative role of genomics and proteomics in prognosis (39).”
BackgroundRalBP1 is necessary for metastasis of human cancer cell lines
Wu, Z., Owens, C., Chandra, N., Popovic, K., Conaway, M., & Theodorescu, D. (2010) · Neoplasia · doi:10.1593/neo.101080 · Cited by 70
“In prostate cancer, RalA seems to be necessary for these processes [5], and the expression of this protein is associated with human tumor progression [18].”
BackgroundBreaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz006 · Cited by 50
“The microarray-based prostate cancer (GSE3325) gene expression dataset [2], SLE gene expression dataset (GSE65391) and HBV dataset (GSE69590) were obtained from the Gene Expression Omnibus (GEO) database.”
MethodDysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group
Wang, W.-X., Kyprianou, N., Wang, X., & Nelson, P. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1684 · Cited by 48
Barfeld, S. J., East, P., Zuber, V., & Mills, I. G. (2014) · BMC Medical Genomics · doi:10.1186/s12920-014-0074-9 · Cited by 47
“about a decade ago and consisting of a small number of whole tissue sections [8].”
Background
Metadata
- Authors
- Varambally, S., Yu, J., Laxman, B., Rhodes, D. R., Mehra, R., Tomlins, S. A., Shah, R. B., Chandran, U., Monzon, F. A., Becich, M. J., Wei, J. T., Pienta, K. J., Ghosh, D., Rubin, M. A., & Chinnaiyan, A. M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-11
- Volume
- 8
- Issue
- 5
- Pages
- 393-406
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1967990571
- Cited by
- 800
- References
- 60
- FWCI
- 24.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.